ConserV Bioscience
ConserV Bioscience is a late-stage vaccine development company focused on creating safe and effective vaccines that offer broad protection against rapidly mutating viruses. They utilize a proprietary in silico platform to identify conserved regions of viral proteins to develop vaccines that provide lasting immunity against emergent pandemic strains, with a focus on viruses such as influenza, coronavirus, and mosquito-borne diseases.
Industries
Nr. of Employees
small (1-50)
ConserV Bioscience
Products
Mosquito-borne disease vaccine (AGS-v)
Vaccine candidate targeting mosquito-borne pathogens designed to induce protective immune responses against relevant conserved viral regions.
Universal influenza vaccine candidate (FLU-v)
Synthetic multi-epitope peptide vaccine comprising peptides from conserved internal influenza proteins (M1, M2, NP) designed to elicit cell-mediated immunity with cross-strain coverage.
Pan-coronavirus vaccine candidate (UNICOR-v)
Vaccine development project aimed at eliciting immunity against a broad range of coronaviruses across multiple genera by targeting conserved viral regions.
Arbovirus vaccine platform (ARBO-SAL)
Platform approach to develop vaccines against arboviruses with the intent to provide durable protection via conserved-antigen targeting.
Malaria vaccine candidate (collaborative evaluation)
Vaccine candidate under evaluation in collaboration with an external military research institute supported by a peer-reviewed research grant.
Mosquito-borne disease vaccine (AGS-v)
Vaccine candidate targeting mosquito-borne pathogens designed to induce protective immune responses against relevant conserved viral regions.
Universal influenza vaccine candidate (FLU-v)
Synthetic multi-epitope peptide vaccine comprising peptides from conserved internal influenza proteins (M1, M2, NP) designed to elicit cell-mediated immunity with cross-strain coverage.
Pan-coronavirus vaccine candidate (UNICOR-v)
Vaccine development project aimed at eliciting immunity against a broad range of coronaviruses across multiple genera by targeting conserved viral regions.
Arbovirus vaccine platform (ARBO-SAL)
Platform approach to develop vaccines against arboviruses with the intent to provide durable protection via conserved-antigen targeting.
Malaria vaccine candidate (collaborative evaluation)
Vaccine candidate under evaluation in collaboration with an external military research institute supported by a peer-reviewed research grant.
Services
Collaborative vaccine R&D and consortium participation
Participates in and coordinates multi-party, grant-funded research projects and industrial R&D consortia to develop and manufacture broadly protective vaccines.
Collaborative vaccine R&D and consortium participation
Participates in and coordinates multi-party, grant-funded research projects and industrial R&D consortia to develop and manufacture broadly protective vaccines.
Expertise Areas
- Vaccine antigen design focused on conserved viral regions
- Pre-clinical immunogenicity assessment
- Clinical trial design and execution for vaccine candidates
- Nucleic-acid vaccine development and delivery
Key Technologies
- In silico epitope mapping
- HLA coverage analysis
- Synthetic multi-epitope peptide design
- mRNA vaccine constructs